William McCann, MD
Allergy & Immunology · Asheville, NCNPI 1922098250
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,275 of the $486,450 with a category attached, or 67.1%. AstraZeneca accounts for 67.0% of it on its own, with 28 other manufacturers making up the rest. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 670 payments — averaging $726.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$326K
- Regeneron Healthcare Solutions, Inc.$54K
- ARS Pharmaceuticals Operations, Inc.$45K
- Novartis$26K
- Genentech USA, Inc.$11K
- Sanofi$10K
- plus $15K from 23 others
Across 5 payments — averaging $44,792 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$224K
What the payments were for
- Consulting fees$116,05724%
- Speaking & faculty fees$326,27567%
- Travel & lodging$25,6495%
- Food & beverage$18,2904%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 387 | $325,918 |
| Regeneron Healthcare Solutions, Inc. | 82 | $54,230 |
| ARS Pharmaceuticals Operations, Inc. | 28 | $44,919 |
| Novartis | 21 | $26,072 |
| Genentech USA, Inc. | 21 | $10,676 |
| Sanofi | 13 | $9,733 |
| Amgen(2 entities) | 11 | $5,015 |
| Aimmune Therapeutics, Inc. | 6 | $3,420 |
| Astrazeneca UK Limited | 1 | $1,860 |
| GSK | 53 | $876 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $849 |
| Alk-abello, Inc | 9 | $630 |
| Blueprint Medicines Corporation | 7 | $589 |
| Eyevance Pharmaceuticals LLC | 1 | $500 |
| CSL Behring | 3 | $249 |
| Grifols USA, LLC | 3 | $159 |
| Siemens Medical Solutions USA, Inc. | 1 | $143 |
| Optinose US, Inc. | 3 | $137 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 3 | $110 |
| Biocryst US Sales Co., LLC | 1 | $70 |
| Hospira, Inc. | 3 | $50 |
| Pfizer | 2 | $28 |
| ADMA Biomanufacturing LLC | 1 | $21 |
| Jubilant Hollisterstier LLC | 1 | $21 |
| Kaleo, Inc. | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$486,450 in reported general payments places this provider in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirazyrIcatibant Acetate | 11 | $361,978 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 21 | $64,663 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $64,652 |
| XolairOmalizumab | 11 | $61,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $46,160 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $19,841 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $18,125 |
| Spiriva RespimatTiotropium Bromide | 17 | $13,489 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $4,996 |
| Ventolin HfaAlbuterol Sulfate | 55 | $4,596 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,151 |
| Epinephrine | 20 | $4,053 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,821 |
| Azelastine Hcl | 70 | $2,757 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Firazyr | $849 | $361,97811 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $876 | $68,43694 claims |
| Grifols USA, LLCGamunex-C | $159 | $64,66321 claims |
| CSL BehringHizentra | $249 | $64,65211 claims |
| AstraZenecaSymbicort | $325,918 | $19,84172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Asheville
- David BrownAsheville$129K
- Christopher CopenhaverAsheville$88K
- David CypcarAsheville$40K
- Elise CoulsonAsheville$16K
- Jordan SmallwoodAsheville$13K
- John van WyeAsheville$11K
- Catherine CranfordAsheville$7K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.